What this study is
The Aim of this Study is to examine the feasibility of using quantitative sensory testing procedures, widely applied to the experimental study of sensory processing in humans both with and without various pain syndromes, to now characterize the psychophysical properties of neuropathic pain that has developed as a consequence of cancer therapy. Skin punch biopsies will be performed in patients with chemotherapy-induced pain to determine whether the impairment of nerve function is due to actual retraction or loss of innervation to the skin in areas affected by sensory disturbance.
What's being tested
- Sensory Tests
Intervention · OTHER
Tests to find the threshold at which perceive stimuli.
Study details
- Official title
- Psychophysical Studies of Cancer Therapy-Induced Pain: A Feasibility Study
- Sponsor
- M.D. Anderson Cancer Center
- Conditions
- Advanced Cancer · Pain
- Enrolling
- 450 people
- Starts
- 2001-01-23
- Est. completion
- 2028-04-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Since moderate pain, albeit brief, will be induced, this feasibility project will be limited to consenting adults, 18 years old or older, in which there is also a well established QST database.
- The subjects must be able to understand the nature of the study and have signed consent.
- The patients must either: a) have pain that has developed as a consequence of cancer therapy with either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation. OR b) have no pain that has developed as a consequence of cancer therapy, and are just entering chemotherapy with taxanes, vinka alkaloids, bortezomib, thalidomide, or platinum-based compounds
- (For Healthy Controls) Willing to participate and have signed an informed consent.
You can't join if
- Patients who refuse to participate or who are determined incapable of completing the research.
- (For Healthy Controls) Receiving anti-coagulants, immunosuppressed or diabetic.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Texas MD Anderson Cancer Center
Houston, Texas, United States
- Patrick M. Dougherty, PhD · Principal investigator
Recruiting
Study team
Sponsor
M.D. Anderson Cancer Center
Study ID ANS00-339
Principal investigator
Patrick M. Dougherty, PhD
M.D. Anderson Cancer Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.